Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003
Shots:
- Earendil Labs has granted Sanofi exclusive global rights to develop HXN-1002 & HXN-1003 bispecific antibodies for autoimmune & inflammatory bowel diseases
- As per the deal, Earendil Labs will receive $125M upfront, ~$1.72B in development & commercial milestones, incl. a near-term $50M payment, & tiered royalties ranging from high-single to low-double digits
- Developed using Earendil Labs' AI discovery & research platform, HXN-1002 targets α4β7 & TL1A to treat mod. to sev. UC & Crohn's disease, while HXN-1003 inhibits TL1A & IL-23 pathways, showing synergistic efficacy in preclinical colitis & skin inflammation models
Ref: Prnewswire | Image: Sanofi
Related News:- Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
